Spectrum's belinostat shrinks tumors in blood cancer study

12/26/2012 | Reuters

Spectrum Pharmaceuticals' investigational drug belinostat achieved the primary goal of shrinking tumors in a Phase II trial involving patients with relapsed/refractory peripheral T-cell lymphoma who had not responded to at least one previous treatment. The firm plans to submit the drug, which has fast-track and orphan-drug status, for marketing approval by the middle of next year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX